[
    {
        "text": "[♩INTRO]",
        "start": 0.0,
        "duration": 3.26
    },
    {
        "text": "More than eighteen hundred people have died\nso far",
        "start": 3.42,
        "duration": 2.39
    },
    {
        "text": "in the second largest Ebola outbreak in history.",
        "start": 5.81,
        "duration": 3.14
    },
    {
        "text": "But doctors on the front lines now have a\nnew weapon.",
        "start": 8.95,
        "duration": 3.08
    },
    {
        "text": "Two of them, actually, because a clinical\ntrial in",
        "start": 12.03,
        "duration": 2.63
    },
    {
        "text": "the Democratic Republic of the Congo revealed\ntwo new treatments",
        "start": 14.66,
        "duration": 4.279
    },
    {
        "text": "which can cure the disease.",
        "start": 18.939,
        "duration": 1.731
    },
    {
        "text": "The Ebola virus kills about three-quarters\nof people",
        "start": 20.67,
        "duration": 3.51
    },
    {
        "text": "who don’t receive medical care.",
        "start": 24.18,
        "duration": 1.71
    },
    {
        "text": "And obviously, that’s a lot.",
        "start": 25.89,
        "duration": 1.6
    },
    {
        "text": "But what’s really scary how many still die\nwith treatment.",
        "start": 27.49,
        "duration": 4.25
    },
    {
        "text": "The standard treatment is a drug called ZMapp,",
        "start": 31.74,
        "duration": 2.35
    },
    {
        "text": "but it only brings the average mortality rate\ndown to 49%.",
        "start": 34.09,
        "duration": 3.26
    },
    {
        "text": "So in November of 2018, researchers started\na clinical trial",
        "start": 37.35,
        "duration": 2.889
    },
    {
        "text": "to test several new drugs.",
        "start": 40.239,
        "duration": 2.09
    },
    {
        "text": "One was an antiviral compound called Remdesivir,",
        "start": 42.329,
        "duration": 2.521
    },
    {
        "text": "which is designed to gum up one of the main\nproteins the virus needs to replicate.",
        "start": 44.85,
        "duration": 4.189
    },
    {
        "text": "The other two attack the virus with antibodies:",
        "start": 49.039,
        "duration": 2.7
    },
    {
        "text": "proteins made by the immune system which grab\nonto potential pathogens",
        "start": 51.739,
        "duration": 4.16
    },
    {
        "text": "so they can be destroyed.",
        "start": 55.899,
        "duration": 1.56
    },
    {
        "text": "Antibodies can be very effective treatments",
        "start": 57.459,
        "duration": 2.24
    },
    {
        "text": "if you can get them to stick.",
        "start": 59.699,
        "duration": 1.721
    },
    {
        "text": "The trouble with Ebola is that it can change\nshape and mask itself from",
        "start": 61.42,
        "duration": 3.54
    },
    {
        "text": "the immune system, so it’s been hard to\nfind an antibody that always works.",
        "start": 64.96,
        "duration": 3.99
    },
    {
        "text": "So, one biotech company used special animal\nmodels to develop three different antibodies,",
        "start": 68.95,
        "duration": 5.55
    },
    {
        "text": "which they then combined to make REGN-EB3\nor just EB3.",
        "start": 74.5,
        "duration": 5.38
    },
    {
        "text": "Other researchers looked for solutions in\nliving people.",
        "start": 79.88,
        "duration": 2.83
    },
    {
        "text": "They managed to clone an antibody from someone",
        "start": 82.71,
        "duration": 2.57
    },
    {
        "text": "who survived an Ebola outbreak in the 90s,\nand called that mAb114.",
        "start": 85.28,
        "duration": 4.329
    },
    {
        "text": "The trial compared these three new treatments\nto ZMapp",
        "start": 89.609,
        "duration": 4.561
    },
    {
        "text": "in nearly seven hundred patients over the\npast nine or so months.",
        "start": 94.17,
        "duration": 4.009
    },
    {
        "text": "And unfortunately, the antiviral didn’t\ndo much.",
        "start": 98.179,
        "duration": 2.711
    },
    {
        "text": "The antibodies, though—they were amazing.",
        "start": 100.89,
        "duration": 2.969
    },
    {
        "text": "A single dose of the lone antibody brought\nmortality rates down to 34%,",
        "start": 103.859,
        "duration": 5.531
    },
    {
        "text": "and one dose of the EB3 cocktail dropped them\nall the way to 29%.",
        "start": 109.39,
        "duration": 3.759
    },
    {
        "text": "But an even bigger win came for patients who\nwere treated with one of these",
        "start": 113.149,
        "duration": 3.79
    },
    {
        "text": "within three days of getting sick — between\n89-94% of them survived!",
        "start": 116.939,
        "duration": 5.93
    },
    {
        "text": "That’s so effective that the researchers\ndecided to call off the trial right there",
        "start": 122.869,
        "duration": 3.95
    },
    {
        "text": "so they could give everyone the potential\ncures.",
        "start": 126.819,
        "duration": 2.481
    },
    {
        "text": "Now, doctors will start a new trial with just\nEB3 and mAb114 to see how they compare,",
        "start": 129.3,
        "duration": 6.49
    },
    {
        "text": "and both drugs will be made available to people\nwho aren’t part of the research.",
        "start": 135.79,
        "duration": 3.31
    },
    {
        "text": "And Ebola isn’t the only deadly disease\nwe’ve gotten closer to curing.",
        "start": 139.1,
        "duration": 4.08
    },
    {
        "text": "Just last week, the US FDA approved a new\ntreatment for antibiotic-resistant tuberculosis",
        "start": 143.18,
        "duration": 5.419
    },
    {
        "text": "a critical step towards getting the drugs\nto where they’re needed most.",
        "start": 148.599,
        "duration": 4.051
    },
    {
        "text": "Tuberculosis, or TB, is a bacterial lung infection.",
        "start": 152.65,
        "duration": 2.97
    },
    {
        "text": "And we’ve had vaccines and antibiotics for\nit for years now.",
        "start": 155.62,
        "duration": 2.91
    },
    {
        "text": "But about ten million people around the world\nstill get TB,",
        "start": 158.53,
        "duration": 4.01
    },
    {
        "text": "and one particular strain is resistant to\nour usual treatment methods,",
        "start": 162.54,
        "duration": 4.11
    },
    {
        "text": "making it extremely deadly.",
        "start": 166.65,
        "duration": 1.919
    },
    {
        "text": "The vast majority of people who contract drug\nresistant TB",
        "start": 168.569,
        "duration": 2.651
    },
    {
        "text": "die before they’re even diagnosed,",
        "start": 171.22,
        "duration": 2.599
    },
    {
        "text": "and even with treatment, only 34% of them\nmake it.",
        "start": 173.819,
        "duration": 3.161
    },
    {
        "text": "Plus, that treatment involves taking upwards\nof 40 pills a day for up to two years,",
        "start": 176.98,
        "duration": 5.01
    },
    {
        "text": "and can have some serious side effects.",
        "start": 181.99,
        "duration": 2.32
    },
    {
        "text": "Obviously, it’d be great if we had an easier,\nmore effective option.",
        "start": 184.31,
        "duration": 3.429
    },
    {
        "text": "But developing new antibiotics is really expensive,",
        "start": 187.739,
        "duration": 3.741
    },
    {
        "text": "and few companies are willing to make the\ninvestment,",
        "start": 191.48,
        "duration": 2.209
    },
    {
        "text": "especially when the majority of people with\nTB are poor",
        "start": 193.689,
        "duration": 3.481
    },
    {
        "text": "and can’t afford expensive drugs.",
        "start": 197.17,
        "duration": 2.34
    },
    {
        "text": "Luckily, nonprofits like the TB Alliance have\nstepped up.",
        "start": 199.51,
        "duration": 2.78
    },
    {
        "text": "And it’s thanks to their influx of cash",
        "start": 202.29,
        "duration": 1.91
    },
    {
        "text": "that the antibiotic which just won over the\nFDA, called pretomanid, was developed.",
        "start": 204.2,
        "duration": 4.13
    },
    {
        "text": "A clinical trial of the drug which began in\n2015 found",
        "start": 208.33,
        "duration": 3.67
    },
    {
        "text": "that, when pretomanid was combined with two\nother antibiotics,",
        "start": 212.0,
        "duration": 3.62
    },
    {
        "text": "almost 90% of people recovered in six months.",
        "start": 215.62,
        "duration": 3.77
    },
    {
        "text": "And patients only have to take five pills\na day!",
        "start": 219.39,
        "duration": 2.83
    },
    {
        "text": "That overwhelming success convinced the FDA\nto approve of the three-drug regimen.",
        "start": 222.22,
        "duration": 4.56
    },
    {
        "text": "And when the FDA approves of something,",
        "start": 226.78,
        "duration": 1.87
    },
    {
        "text": "international organizations often follow suit.",
        "start": 228.65,
        "duration": 2.68
    },
    {
        "text": "But there are still challenges ahead.",
        "start": 231.33,
        "duration": 2.07
    },
    {
        "text": "Bacterial infections like TB are more common\nin impoverished areas of the world,",
        "start": 233.4,
        "duration": 4.449
    },
    {
        "text": "so antibiotics need to be priced in a way\nthat poorer patients can afford them.",
        "start": 237.849,
        "duration": 4.371
    },
    {
        "text": "And even non-profits with the best intentions\ncan run out of money.",
        "start": 242.22,
        "duration": 3.84
    },
    {
        "text": "So they need to get manufacturers to agree\nto price the drug reasonably.",
        "start": 246.06,
        "duration": 3.37
    },
    {
        "text": "Those negotiations are going on right now,\nso let’s all keep our fingers crossed.",
        "start": 249.43,
        "duration": 5.009
    },
    {
        "text": "Thanks for watching this episode of SciShow\nNews!",
        "start": 254.439,
        "duration": 1.64
    },
    {
        "text": "But before you go, there’s one more thing\nI’d like to mention.",
        "start": 256.079,
        "duration": 3.041
    },
    {
        "text": "It’s not exactly news, but if you’re the\nkind of person",
        "start": 259.12,
        "duration": 2.16
    },
    {
        "text": "who likes to jazz up your jacket or backpack\nwith an awesome pin,",
        "start": 261.28,
        "duration": 3.36
    },
    {
        "text": "you might want to head on over to DFTBA.com/scishow.",
        "start": 264.64,
        "duration": 3.43
    },
    {
        "text": "Our August Pin of the Month, which features\nthe Curiosity rover,",
        "start": 268.07,
        "duration": 3.25
    },
    {
        "text": "is only on sale for another week!",
        "start": 271.32,
        "duration": 1.56
    },
    {
        "text": "And I know you don’t want to miss out on\nsuch a stylish, adorable tribute.",
        "start": 272.88,
        "duration": 3.72
    },
    {
        "text": "[♩OUTRO]",
        "start": 276.6,
        "duration": 10.02
    }
]